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Abstract
Genetic testing for spinocerebellar ataxia (SCA) is used in diagnosis of rare movement disorders.
Such testing generally does not affect treatment, but confirmation of mutations in a known gene
can confirm diagnosis and end an often years-long quest for the cause of distressing and disabling
symptoms. Through interviews and a web forum hosted by the National Ataxia Foundation,
patients and health professionals related their experiences with patents’ impact on access to
genetic testing for SCA. In the United States, Athena Diagnostics holds either a patent or an
exclusive license to a patent in the case of 6 SCA variants (SCA1-3 & 6-8) and two other
hereditary ataxias (Friedreich’s Ataxia and Early Onset Ataxia). Athena has enforced its exclusive
rights to SCA-related patents by sending cease and desist letters to multiple laboratories offering
genetic testing for inherited neurological conditions, including SCA. Roughly half of web forum
respondents had decided not to get genetic tests. Price, coverage and reimbursement by insurers
and health plans, and fear of genetic discrimination were the main reasons cited for deciding not to
get tested. Price was cited as an access concern by the physicians, and as sole US provider,
coverage and reimbursement depend on having payment agreements between Athena and payers.
In cases where payers do not reimburse, the patient is responsible for payment, although some
patients can apply to the voluntary Athena Access and Patient Protection Programs offered by the
company.
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Views of patients and health professionals about the impact of patents on access to genetic
testing for spinocerebellar ataxia (SCA) were sampled via a web forum. Questions about
access to genetic testing were posted on the website of the National Ataxia Foundation
(NAF), which agreed to host the web forum. The web forum was supplemented by
interviews with three neurologists and a laboratory director. Both the web forum and
interviews focused on perceptions of whether patents impede neurological patients from
using diagnostic tests for the most common autosomal dominant forms of spinocerebellar
ataxia.
SCA is not a single condition, but a group of progressive neurological genetic disorders with
common symptoms and disparate genetic causes. Genetic testing plays a direct role in
identifying the molecular defect in some cases.
Patents were generally not perceived to be a major direct impediment in most cases,
although they reduced access to the degree they increased the cost of testing borne directly
by patients. Most SCA genetic testing in the United States is carried out by Athena
Diagnostics, which has in-licensed exclusive patent rights from various holders of SCA
patents, mainly universities and nonprofit research institutions. Some genes involved in SCA
testing are not patented at all.
Price and concern about genetic discrimination both appear to reduce patient use of genetic
tests. The decision not to get tested holds even for those who have progressed far into a
diagnostic workup. SCA is a relatively rare syndrome and many genes are involved. The
cost of testing can be as high as $7300, and only six out of fourteen patients surveyed who
sought testing received reimbursement for testing from their insurance carriers. Yet clinical
testing requires CLIA certification and testing for many genes, so patients are generally
grateful there is a test provider.
Athena offers a “Patient Protection Program” that caps out-of-pocket payments at 20% of
the price for cases where Athena directly bills the patient’s insurer. However, this likely
covers only a small minority (10–15%) of patients tested by Athena. Some patients who
availed themselves of Athena’s Patient Protection Program appreciated the out-of-pocket
payment caps. Under this program, Athena takes responsibility for seeking reimbursement
from payers and insurers for the other 80%. Athena also has an “Athena Access” program
for those who cannot afford the 20% copay, which entails case-by-case review by Athena;
analysis of SEC filings suggests that this covers relatively few patients. The 20% copay cap
for patient outlays under the Patient Protection Program is a standard option, although many
patients appear not to know about it, and those in certain health programs are not eligible for
it. Athena did not provide statistics on the percentage of patients covered by these two
programs, so we are unable to estimate their actual impact. Since the program is
discretionary and operated by Athena, independent data about how many people use it,
which insurers and health programs are covered, and other details are not available.
SACGHS might consider requesting details about both the Patient Protection Program and
Athena Access from the company, since these details were not shared with us.
We cannot estimate the population prevalence or magnitude of the effects because of the
highly selected nature of our sample. The website respondents, however, do indicate the two
main reasons that patients with rare genetic conditions may not use genetic tests even when
they would like to have the results of them: fear of discrimination and cost.
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Spinocerebellar ataxia (SCA) is a designation given to a rare subset of autosomal dominant
cerebellar diseases characterized by loss of cerebellar cells. (Spinocerebellar ataxia is also
associated with other patterns of inheritance, both autosomal recessive [SCAR] and X-
linked (SCAX), but these are even more rare and less well characterized and therefore less
relevant for commercial genetic testing.) Symptoms include ataxia, or irregular movement
due to loss of neural control, and often also other symptoms attributable to loss of brainstem
and spinal cord function.1, 2 Ataxia is a common symptom found in conditions from chronic
alcoholism to stroke. SCA accounts for less than 5% of the ataxic population, an estimated
prevalence of 1–5:100,000.3–5 While accounting for only one in twenty cases of ataxia, the
autosomal dominant SCA syndromes are nonetheless much more common than the other
genetic forms, which are quite rare.
The severity and types of symptoms vary among the cerebellar ataxias. Diagnosis often
takes years and may entail many visits to a succession of physicians and other health
professionals, especially when it is a “proband case,” or the first known case in a family
cluster. Once a first case is found in a family and confirmed as an inherited condition,
genealogical tracing may identify other cases in the family. There are currently more than 30
identified variants of SCA (named SCA1–8, and 10–25 see Table 1), a number that is
constantly expanding. Each variant has the symptom of ataxia, however the secondary
symptoms can differ greatly. The symptoms associated with variants of SCA have
significant overlap, so purely clinical symptom clusters rarely specify a particular mutation
without DNA or protein testing. The vagueness with which each variant is described can
make purely clinical diagnosis without genetic testing difficult, although there have been
many attempts to design clinical scales using symptom correlations to hone in on a diagnosis
(Figure 1).6, 7 There is no known cure for any subtype of SCA, and treatment often involves
addressing individual symptoms as they appear.
Before 1982, symptoms that now distinguish the various subtypes of SCA were diagnosed
as olivopontine cerebellar atrophy (OPCA), a classification that encompassed a host of
cerebellar diseases.8 Later, a clinical classification was proposed for a subset of these
diseases based on mode of inheritance and secondary neurological symptoms not associated
with the cerebellum.9 These classifications, known as the autosomal dominant cerebellar
ataxias (ADCAs), were subdivided into classes I, II, and III. This diagnostic refinement
allowed neurologists to distinguish ataxias according to their accompanying symptoms,
among those being: peripheral nerve damage and dementia (ADCA I), macular and retinal
degeneration (ADCA II), and an especially severe late-onset pure form of ataxia (ADCA
III).
Eventually, as genetic research was incorporated into the classification along with
symptoms, these conditions were divided further into the more than 30 conditions now
known as SCA.6, 9, 10 ADCA I was supplanted by SCA1–3, ACDA II was replaced with
SCA7, and ACDA III was divided into SCA4–6 and 11. The classification has “gone
molecular.” It is now based on mutations in genes that encode proteins affecting nerve
function. Some mutations are associated with changes in proteins that conduct charged
particles through cell membranes (“channel” proteins), receptors, or other surface proteins
on nerve cells. Despite the increased specificity in diagnosis, treatment has changed little.
Progress in understanding the molecular details has not yet translated to better treatment.
The primary benefits of SCA genetic testing for a patient are precision of prognosis, some
reassurance from an accurate characterization of the molecular defect, an ability to diagnose
those who are affected or presymptomatic among relatives, and the ability to test for a
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known mutation during preimplantation diagnosis or prenatal diagnosis in the progeny of an
affected person.
We focus on the six most common forms, SCA1–3 & SCA 6–8.
Symptoms and Pathology Of SCA Subtypes
SCA1 has pan-cerebellar symptoms that typically begins in a patient’s fourth decade, with
an average duration of fifteen years (Table 1). Cerebellar symptoms include an atrophy of
Purkinje cells, loss of afferent projections into the cerebellar cortex, and atrophy of
dentatorubral pathways. Non-cerebellar symptoms include signs associated with damage to
the dorsal columns and cranial nerve nuclei. SCA1 maps to chromosome 6p23 in the
ataxin-1 gene and is a CAG trinucleotide repeat disorder (i.e., caused by expanded number
of those three base pairs inserted as repeats into the gene’s DNA). SCA1 is estimated to
represent 5.6% of autosomal dominant SCA ataxias.3
SCA2, in addition to cerebellar symptoms found with olivopontocerebellar atrophy, is
associated with marked loss or slowing of saccadic eye movements, dementia, and other
peripheral neuropathy. Patients with SCA2 can show their first symptoms from age 2 to age
65, a huge range in age of onset, with an average duration of 10–15 years from onset to
death.11 SCA2 maps to chromosome 12q24.1 in the ataxin-2 gene and is a CAG
trinucleotide repeat disorder. SCA2 is one of the most common of the autosomal dominant
cerebellar ataxias accounting for an estimated 15.2% of SCA occurrences.3
SCA3, also known as Machado-Joseph disease, is characterized by cerebellar signs
including degeneration of the dentate and vestibular nuclei, with no degeneration of the
cerebellar cortex. Additional symptoms include extrapyramidal, motor cranial nerve,
anterior horn, posterior root ganglion, and spinopontine symptoms. SCA3 symptoms begin
in the fourth decade with a typical duration of ten to fifteen years. SCA3 maps to
chromosome 14q24.3-q32.2 in the ataxin-3 gene and is also a CAG trinucleotide repeat
disorder. First described as Machado-Joseph disease, SCA3 accounts for 84% of autosomal
dominant ataxias in ethnic Portuguese and 50% in ethnic German populations. In the US,
SCA3 accounts for approximately 21% of dominant ataxias. The severity of symptoms
correlates with the number of CAG repeats.12
SCA6 is an autosomal dominant ataxia that has a variable presentation, classified as three
separate syndromes. The SCA6 syndromes are episodic ataxia, cerebellar ataxia plus
brainstem or long tract degeneration, or pure cerebellar ataxia. Additional symptoms include
a coarse gaze-evoked nystagmus, downbeat nystagmus on lateral gaze, and poor suppression
of eye movement by vision.13 SCA6 is a slowly progressing late-onset version of SCA that
begins in the fifth or sixth decade with a typical duration of more than 25 years. The SCA6
mutation has been identified as a CAG expansion located at 19p13, a subunit of the voltage-
gated calcium channel CACNL1A4. SCA6 accounts for approximately 15% of autosomal
dominant ataxias in the US.
In addition to cerebellar symptoms and ataxia, SCA7 is associated with retinopathy or
blindness. Beginning in the third or fourth decade, SCA7 is a slowly progressive ataxia,
lasting an average of twenty years. Mapped to 3p21.1-p12, which encodes ataxin-7, SCA7 is
a CAG repeat disorder as well. SCA7 accounts for roughly 5% of dominantly inherited
ataxias in the United States. It is sometimes associated with genetic anticipation (earlier
onset in successive generations, usually indicative of expansions of trinucleotide repeats)
and severe childhood onset.
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SCA8 is a less severe form of SCA, with symptoms including hyperreflexia, decreased sense
of vibration, ataxic dysarthria (lack of control of joints), impaired smooth-pursuit eye
movement, horizontal nystagmus, and atrophy of the cerebellar vermis and hemispheres.
SCA8 begins in the fourth decade and is not associated with shortened lifespan. SCA8 has
been mapped to 13q21, which encodes ataxin-8 and is a CAG/CTG repeat disorder. SCA8
accounts for 2–5% of autosomal dominant ataxias in the US.
Diagnosing Spinocerebellar Ataxia
When first diagnosing or treating an ataxic patient, one of the first lines of evidence is
family history. Like many diseases with known genetic causes, a family history that reveals
multiple family members afflicted with similar clinical conditions can indicate that diagnosis
of SCA should be considered.
While an ataxic patient whose family history includes a genetically confirmed diagnosis of a
SCA subtype is an ideal candidate for genetic testing, such cases are unusual. Most family
histories contain no results from genetic testing because it is a relatively new technology. If
ataxic symptoms exist in a family record, a previous diagnosis is likely to reflect a
classification given to the disease at the time of diagnosis. Despite a dated classification,
these histories are still valuable for diagnosing hereditary ataxias (Figure 2).
Family history is unavailable in many cases. A patient may be adopted, where heredity is
impossible to trace through standard pedigree tracing. A patient may come from a family
that has had little exposure to modern medicine and record keeping or adoption. Due to the
late onset of some hereditary ataxias, not all families have had life expectancies long enough
for symptoms to be observed.9 Many die without a definitive diagnosis, and stigma
associated with uncontrollable movement can lead to cases being “hidden” from family
discussion and result in incomplete pedigrees.
An initial neurological consultation is also intended to resolve whether the ataxia is acquired
(e.g., related to alcohol use, infection, or other known syndromes) or sporadic. Acquired
ataxia refers to cases with no known genetic component. These can be highly variable from
case to case.9, 10 Common causes of acquired ataxia include chronic alcoholism, stroke,
multiple sclerosis, vitamin deficiency, and metabolic deficiencies.14–16 In some cases,
identifying the source of an acquired ataxia can lead to a relief or even reversal of
symptoms.
Sporadic ataxia is a diagnosis given to a subset of patients who have ataxia with no known
hereditary or acquired components. This residual classification is broken into either pure
cerebellar or ‘cerebellar plus,’ depending on whether there are symptoms in addition to
ataxia.6, 10, 17 Regardless of whether the ataxia appears to be hereditary, sporadic or
acquired upon an initial evaluation, an ataxic patient will generally undergo a complete
neurological evaluation and an MRI scan.
After one or several MRI scans, the neurologist may observe cerebellar atrophy, or loss of
cerebellar tissue. In addition to atrophy, the neurologist may observe signs and symptoms of
a progressive loss of function in systems associated with the cerebellum. Symptoms can
include gait disruption, nystagmus, vertigo, or general lack of coordination. Secondary non-
cerebellar symptoms including impaired cognition, memory, and vision can also point to
SCA.
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INTELLECTUAL PROPERTY LANDSCAPE – ATHENA DIAGNOSTICS
Many genetic tests for SCA are available only from Athena Diagnostics, including the most
commonly used SCA genetic tests. There are currently 15 variants of SCA for which genetic
testing is available. Athena Diagnostics holds the patent or has exclusive license to 12
patents that identify 6 SCA variants (SCA1–3 & 6–8) and two other hereditary ataxias
(Friedreich’s Ataxia and Early Onset Ataxia) included in their Complete Ataxia Panel
(Table 3). These variants are the most commonly occurring, accounting for roughly 60–80%
of known SCA cases, depending on the patient’s country of origin.18–20 Athena was also
granted a nonexclusive license by Baylor Medical College for US6855497, which covers
methods for detecting SCA-10 (Personal communication with Teresa L. Rakow, Sr.
Licensing Associate Baylor Licensing Group Baylor College of Medicine), and Athena also
does testing for SCA5, 13, 14 and 17.
Of the 12 patents listed by Athena, half are licensed from the University of Minnesota.
Three others are from academic institutions (two through Research Foundation, one from
Baylor) and only one is assigned to Athena itself. It thus appears that at least 9 of 12 (75%)
are licensed from academic institutions and one arose from in-house R&D at Athena.
Athena Diagnostics has enforced its exclusive licenses and is widely assumed to be the sole
laboratory for the above tests.21, 22 Athena’s legal department has sent “cease and desist”
letters to some laboratories performing SCA genetic tests for which Athena has exclusive
patent rights (Figure 3). In another instance, the Diagnostic Molecular Pathology Laboratory
at the University of California Los Angeles stopped offering testing for SCA over two years
ago, after receiving a “cease and desist” letter from Athena Diagnostics. According to Dr.
Wayne Grody (personal communication), Director of the Laboratory, the terms of the
sublicense offered by Athena Diagnostics were not economically viable for the laboratory.
Attempts to negotiate terms of a sublicense have not been successful to date. It is unclear to
what extent cessation of testing at UCLA has affected patient access to SCA testing. Dr.
Grody indicated that samples are now sent to Athena Diagnostics for clinical testing. Several
other laboratories are also listed on GeneTests.org for adult SCA diagnoses. Comprehensive
Genetics Services offers a complete panel of SCA tests (Table 4) but did not respond to
questions about patents or licensing in phone interviews. We recently became aware that
Boston University reached a settlement with Athena Diagnostics regarding testing for SCA
and several other conditions and no longer offers SCA testing (Personal communication
with Dr. Aubrey Milunsky, Director, Center for Human Genetics, Boston University, May
29, 2008).
Athena Diagnostics does not list prenatal or preimplantation genetic diagnosis. Several labs
listed on GeneTests.org perform these tests. We did not verify or otherwise pursue questions
about prenatal or pre-implantation genetic testing for SCA.
SCA genetic tests can be performed individually for as little as $400, for the least expensive
single-locus test, or as much as $2,335 for full-sequence analysis of the most expensive full-
sequence gene test. The lower cost tests are for known mutations in the second or
subsequent members of a family, once a proband case in that family is characterized. Athena
also offers the Complete Ataxia Panel, a compilation of 18 tests that cover the most
commonly identified SCA mutations for the price of $7,300. This cost includes PCR tests
and tests requiring sequencing (Table 2 & Table 4). The Athena price for the five most
common SCA’s (1, 2, 3, 6 and 7) is $2,300 (if ordered individually, which is the only
option). A university genetics laboratory can reportedly perform the same 5 SCA tests for
$750 (or $1,500 if ordered individually)(Personal communication with a laboratory directory
who requested anonymity).
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Most of Athena Diagnostic’s testing revenue comes from direct billing to hospital and
commercial laboratories that send samples to Athena for patients seen or tested within their
health-care systems. In a public filing with the Securities and Exchange Commission,
Athena indicated that 85% of their revenue comes from this source.23 This is widely known
in the clinical laboratory industry as the most profitable type of billing arrangement: the
sending facility is obligated to pay the full contractual price of testing directly to Athena
regardless of insurance coverage or patient ability to pay; the sending facility then bills the
patient and/or the patient’s third party payer for the cost of testing. Since reimbursement for
this type of testing is often low or absent, the financial burden of poorly reimbursed testing
is thus transferred from Athena to the sending healthcare facility and thence to the patient.
Athena has a formal policy that limits out-of-pocket expenditures for some patients for
whom Athena directly bills the insurer. Athena’s Patient Protection Plan (PPP), charges the
patient 20% of the test fee (the usual copayment for most insurance programs) up front.
After completing the test, if insurance covers the cost of the test, Athena will reimburse the
patient for any payment their insurance makes above 80% of the total bill. Such patients
must have private insurance. If the patient’s insurance does not cover the genetic test,
Athena will limit the patient’s liability to the 20% already paid. This plan requires
preapproval by Athena. There is an additional plan for low-income families, Athena Access.
This is for those who may find the 20% co-pay prohibitive. Athena, upon receiving a request
for a test, will attempt to contact the patient by mail and phone three times in order to enroll
them into the PPP. Athena did not provide specific numbers regarding enrollment
percentages into the PPP. It is also not clear whether this program includes persons whose
only coverage is Medicare or Medicaid. However, the information in the SEC filing cited
above would indicate that this program could apply to no more than 15% of the sources of
revenue for testing at Athena in 2001. The PPP will not provide relief to a patient being
billed by a health-care facility for testing sent to Athena under the common direct billing
arrangement accounting for 85% of Athena’s revenues. There is no way from public sources
to estimate how much of the remaining 15% of revenue might have been reduced by the
company’s PPP or Athena Access programs.
Athena also has a repeat customer program that can also reduce costs borne by patients. If a
patient has a genetic test performed by Athena and receives a positive result, subsequent
family members who request the same test have a greatly reduced price. However, the
impact of this program is probably small because of the low rate of positivity for SCA
testing (only 6% for patients without a known family history of SCA.)24
The benefit of Athena’s licensing SCA patents from several different academic institutions
and combining them with their own patent is that this enables a single laboratory to test for
many variants, and protects the company’s investment in CLIA certification, laboratory
proficiency testing, a sales force to educate neurologists about the tests, and staff to manage
the complex coverage and reimbursement policies of a dizzying array of disparate payers,
insurers, and health plans. The syndromes are relatively rare, and it is possible that this full
range of tests would not be available without the patent incentive.
The counter-argument is that Athena has consolidated IP into an effective temporary
monopoly for genetic testing of the SCA syndromes. It has been vigilant in enforcing its
patent rights, and this has led several laboratories to avoid SCA testing who otherwise might
have offered a testing alternative. As with all patented inventions, this reduces price
competition, means all samples must be sent to an external laboratory, limits alternatives for
verification of test results, and reduces the incentive to introduce cheaper and faster tests
because the current technology is protected by patents. This could, for example, reduce
incentives to develop a chip-based or microarray-bead or sequence-based test using
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alternative technologies, because the patents apply to any technology for assessing patented
mutations or diagnostic methods that entail sequencing or sampling a patented sequence.
Sole provider status also means that Athena effectively becomes the only testing service for
mutations never yet detected (or patented) because the nature of the mutation is not known
when a sample is sent. The means a single private firm becomes the repository for data
needed to determine if a discovered DNA change is actually a disease causing pathogenic
mutation or a benign polymorphism, information that is critically important to clinical
interpretation. Yet Athena does not appear to publish or report such data, leaving reporting
to the disparate groups sending samples to their central laboratory.
Many of these tests were developed through federally funded research and licensed to
Athena. The ultimate payer is often the federal government (through Medicare, Medicaid,
Federal Employee Health Benefit Plan, Tricare, Veterans Health Administration, military
health systems, Indian Health Service, etc.). The patents arising from federally funded
research are subject to Bayh-Dole government use rights. Those government use rights are
clearly not being interpreted to cover even payments channeled through the same federal
Department of Health and Human Services that houses the National Institutes of Health
(NIH) that funded the research (such DHHS payers include Medicare and federal
components of Medicaid, the Indian Health Service and any genetic services covered by the
Health Resources and Services Administration). We do not know if there is a price reduction
for NIH-funded clinical trials and clinical research, because none of the respondents in the
web forum specifically noted participation in such trials and the physicians interviewed did
not mention this. SACGHS could ask Athena if it offers price reduction for genetic testing
associated with federally funded research or allows unlicensed testing for clinical and/or
basic research.
PHYSICIAN UTILIZATION AND ACCESS (INTERVIEWS WITH
NEUROLOGISTS)
To get clinicians’ perspectives on access to genetic testing, we interviewed three
neurologists with varying degrees of expertise with SCA, and a laboratory director. The
neurologists we interviewed are Dr. Octavio de Marchena from the Neurology Associates of
Lynchburg, Dr. James Burke from Duke University Hospital, and Dr. Thomas Bird from the
University of Washington. The laboratory director requested that his/her name be withheld,
and that interview is protected by a certificate of confidentiality (as are others, except when
they were explicitly “on the record”) under the IRB-approved interview protocol we
followed.
Dr. de Marchena is a general neurologist at a regional hospital; he treats all types of
neurological patients and refers cases of ataxia to a subspecialist as needed. Confirmed cases
of hereditary ataxia treated by the Dr. de Marchena are rare, but he has had patients for
whom he has established a positive diagnosis of SCA using genetic testing.
Dr. James Burke is a neurologist who specializes in neurodegenerative diseases at Duke, a
private hospital and clinical outpatient service that is part of a major regional academic
medical center. Dr. Burke does not solely treat patients with movement disorders, but does
have ataxic patients referred to him from both inside and outside Duke. Cases of SCA are
also rare for Dr. Burke, although he orders an estimated 5–10 genetic tests for SCA per year.
Dr. Thomas Bird is a researcher and clinician at the University of Washington and VA Puget
Sound Health Care System, an academic health center with a long and distinguished history
of medical genetics. His research includes the genetics of neurodegenerative diseases. His
patients are often referred to him from all over the country, and many come with the
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expectation that they will have genetic tests performed as part of their visit. Compared to the
other neurologists, Dr. Bird’s patients are more often prescreened as candidates for genetic
testing. Many patients referred to him have been seeking a specific diagnosis for some time.
Many become involved in research studying trinucleotide repeat neurological diseases. Dr.
Bird uses genetic tests much more often than most other neurologists. He estimated that in a
given year he prescribes genetic testing for 35–45 ataxic patients, most patients receiving
testing for multiple variants. When itemized by SCA variant, the number of individual tests
that he orders comes to well over 200 per year. He is also a consultant to Athena. That is, he
is an international expert on SCA.
We asked all three neurologists to describe their use of genetic testing for SCA and the
medical factors most responsible for prescribing tests. We asked them about how they
interact with Athena Diagnostics. In addition, we asked them to describe their interactions
with insurance companies and how insurance and health plan factors affect their use of
genetic testing for SCA. Finally, we asked whether and how reducing the price of testing to
$100 might change their use of genetic testing for SCA.
Clinical Guidelines and Utility of Genetic Testing
Achieving a diagnosis of SCA is more a complex process than a formal algorithm. The
primary reasons for this are that ataxia is a common symptom associated with many
disorders and because there are numerous forms of SCA. It takes substantial evidence from
multiple methodologies (family history, brain imaging and blood tests) over several visits,
often documented in medical records from different providers, before a neurologist
considers a genetic test for SCA. The only time this is not the case is if the family history
contains a specific SCA diagnosis in another family member. (In these cases, while a test
will come earlier, there is still no guarantee of a positive result.)
Considering that genetic testing provides the sole confirming diagnosis of SCA, we probed
further the rationale for delaying genetic tests until after significant clinical evaluation. The
primary reason is low likelihood that genetic testing will be informative in symptomatic
ataxia that is not fully characterized (by ruling out alcohol use, stroke, or multiple sclerosis,
for example). Even the most common form of SCA in US populations (SCA3) is likely to
test negative more than 99% of the time in a patient displaying ataxia without a family
history.3 If a neurologist can follow disease progression long enough, he or she can discern
whether it follows any of the identified classifications of SCA, increasing likelihood of a
positive genetic test. Clinical heterogeneity even among patients afflicted with the same
variant of SCA can make it difficult for a neurologist to identify the SCA genes that should
be tested.
Cost and cost-effectiveness enter into decisions about genetic testing for SCA, but not in a
simple way. While positive results on genetic tests for SCA subtypes provide definitive
diagnosis for ataxia in a patient, the interpretation of a negative result is much less well
defined, and yet negative results are common, even among well-screened patients. Many
patients with clinical ataxia do not have a mutation in any of the genes known to be
associated with SCA. In such cases, the diagnosis will be a clinical, descriptive, or
anatomical one, such as olivopontine cerebellar atrophy.
Cost Effectiveness of Genetic Testing
The primary issue associated with genetic testing for SCA is the low rate of positive results.
The 30 identified spinocerebellar ataxias only account for an estimated 5% of all diagnosed
ataxias.3–5 Genetic tests are available for 12 of the genetic subtypes, representing an
estimated 65–80% of SCA cases (Table 1). Edlefsen et al. compared the cost effectiveness
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of genetic tests.24 In this study, 162 patients were given a total of 282 neurogenetic tests.
The patients were referred for genetic testing by a neurologist based upon family history and
symptoms. The tests included mutations associated with chorea, neuropathy, muscle
weakness, and ataxia. In all, 30.2% of patients received a positive result on a genetic test or
panel of tests corresponding to their symptoms. When only looking at probands, patients for
whom there is no known family history, the positive rate goes down to 21.5%. For tests
related to SCA (SCA1–3, 6–8, 10, 12, 17) the total positive rate for patients was 11% (2/18),
and only 5.9% (1/18) for probands without known family history of other SCA cases. This
“hit” rate for SCA was the lowest of all genetic tests surveyed.
One way to assess testing cost is to estimate the cost per positive test result. The genetic test
for Huntington’s disease costs $300. With a positive result in 71.2% of tests the cost per
positive is $440. For the HD test, the symptoms, family history of chorea, and need to test
only a single locus makes selection of a genetic test straightforward. For the SCA tests, the
cost of the test itself varied from $225 for a single-locus test (for a known mutation in a
second or subsequent family member) to $2,335 for a test requiring sequencing.24 Twenty-
seven genetic tests for SCA, ordered for 18 patients, were either for single variants (17 of
27; SCA3, 7, 8, 10, 12, 14, 17) or as a panel (10 of 27; SCA1–3, & 6–7). With a positive
result rate of 11%, the cost per positive test for SCA was $7,620, the most expensive cost-
per-positive-test studied. Edlefsen et al. note that this cost would increase to over $50,000 if
all tests were sent to Athena Diagnostics (p. 1021).24
Adoption by Clinical Providers
When asked how they obtained SCA genetic testing for a patient, the neurologists said they
simply check a box on a requisition form. A blood sample goes with the form to the
pathology department of their institution. From there, the in-house laboratory either ships
the sample to Athena Diagnostics or performs tests, depending on the test. All three
neurologists stated the testing from Athena was generally consistent and reliable. The
neurologists all stated their personal preference was that the laboratory of their own
institution would perform these tests, especially those that are PCR-based and do not require
sequencing.
Neurologists judged that the price of the test was sometimes problematic, mainly because
insurance would not always reimburse all costs, and patients were not always able to cover
the remaining costs. They considered cost a factor but focused primarily on the clinical
value of genetic testing. The patient might decide to forego testing, but while these
neurologists considered costs, they saw their main task as explaining the clinical value of a
genetic test, and left final determinations about whether a test was worth the cost to their
patients.
To probe price sensitivity, the neurologists were asked a question about whether a decrease
in test pricing to $100 would increase test prescriptions. All three neurologists reiterated
their stance that the limitations of current SCA genetic testing panels place genetic testing
for this condition low on the diagnostic tree and late in the process, so such testing is not
common and therefore not a major cost driver for diagnosis overall. They indicated that
lowering the price to $100 would have little effect on their prescribing pattern. Dr. de
Marchena stated that “any neurologist would call for testing when the symptoms and family
history call for it, regardless of price.” Price is not the main factor in deciding whether to
test, although it is a factor they consider. Dr. Bird noted that any neurologist must take into
account “what value is this to a patient and his family, just giving the test without thought
will not benefit them.” On further reflection, however, Dr. Bird believed he would order
more tests if the cost were substantially lower.
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Lowering the price of testing would not affect the informational value of the test, as
neurologists focus on “benefit to the patient,” and indeed it may be appropriate for patients
to decide for themselves the value of the genetic test, since there are no clinical treatments
that follow from specific genetic diagnosis. The neurologists order the test to provide
clinically relevant information; the patients then must decide the personal value of that
information to them, compared to their out-of-pocket costs and any other costs (needing to
deal with applying for the Patient Protection program, Athena Access, etc.). The benefits of
testing are mainly that the diagnostic work-up can end with a definitive result, a genetic
diagnosis enables more precise prognosis, and it enables risk evaluation and a much more
efficient diagnostic strategy for others related to that person.
The Edelfsen et al. article notes that testing for ataxia is among the most expensive areas for
genetic testing, and that costs would be even higher if patents were enforced rigorously.
They conclude:
For example, the cost per positive result for ataxia testing would increase nearly 7-
fold, to >$50 000, if all tests had been obtained from the laboratory [NB: clearly
referring to Athena Diagnostics] that claims exclusive patent rights for many of
these tests. This increase reflects both higher per-test cost and test packaging that
encourages the ordering of larger panels of tests. Thus, policymakers should be
aware that many of the costs per positive result found in this study may be greatly
increased in the future because of intellectual property restrictions. (p. 1021) 24
Adoption by 3rd Party Payers
While price does not appear to have a strong effect on the number of tests ordered by
neurologists, the contribution of insurance may influence whether patients go ahead and get
genetic testing. When insurance does cover costs for Athena’s Complete Ataxia Panel,
generally leaving an estimated 20%, or $1,500 co-pay, almost all patients who were not
personally opposed to the test would take it. If insurance refused coverage, and patients were
required to pay Athena the full price of $7,300 for the Complete Ataxia Panel, both Dr. Bird
and Dr. Burke report that patients were likely to pay for the test less than half the time.
Additionally, Dr. Burke stated that “for individual tests for a specific SCA variant, insurance
often covered the request because the evidence of its utility was much greater.” Dr Bird
noted that $7,300 self-pay is prohibitive for most patients.
The neurologists all concurred about the inconsistency in insurance companies deciding to
cover a genetic test. The uncertainty surrounding insurance decisions sometimes led to their
postponing genetic testing while awaiting insurer pre-approval and often having to write
time-consuming letters of justification. All these factors tend to reinforce a two-tiered health
system, with full use of genetic testing by the wealthy and many others foregoing SCA
genetic tests.
PATIENT PERSPECTIVES
We solicited direct patient input through a web forum. The mission of the National Ataxia
Foundation (NAF, www.ataxia.org) is to improve the lives of those suffering from ataxia by
offering information, support, and resources. The NAF maintains a bulletin board forum
with over 700 users, many of whom have an ataxia or are family members of someone who
does. The forum supplies information about where to go for diagnosis and how to cope with
the effects of disease. With the cooperation of the NAF, we established a discussion thread
on this forum and asked users to discuss their personal stories regarding genetic testing for
ataxia.
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We began the discussion with a list of questions about genetic testing, about prices, about
the involvement of insurance and health plans, and how the results of the tests affected the
patients. The questions are listed below, followed by a discussion of the responses. The
participants were fully aware they were participating in a public forum. The entire
discussion through 17 October 2007 is Appendix A.
One purpose of the web survey and online forum was to convey information about patient
perspectives to the SACGHS task force. The survey remains online and may expand due to
the patient interest in this topic.
The response was impressive, with 30 responses and 450 views of the website over several
weeks. The responses indicated that patients were passionate about the issue of access to
genetic testing, and their comments provided insight into complexities of genetic testing that
complemented the issues raised by the neurologists, the laboratory director, insurance
companies, and policy makers.
Who responded?
Among the 16 forum users who responded to our questionnaire, there were two major
groups: those diagnosed with a variant of SCA, and others (many of them caregivers or
family members). This is almost surely a highly biased, relatively well-informed and
therefore unrepresentative sample. For our purposes of getting knowledgeable and informed
patient perspectives, however, it was an excellent convenience sample. Of the 16
respondents, 11 had a SCA genetic test performed. Of the 5 without a test, 1 abstained for
fear of genetic discrimination, 1 would have a test performed soon, and the other 3 were not
covered by their insurance and could not pay for the testing themselves. Of the 11
responders that took the test, 6 were covered by their insurance carrier, the others paid out of
pocket. The users who had a diagnosis achieved it through genetic testing by Athena
Diagnostics. Those without an SCA diagnosis either took the test and had negative or
inconclusive results, or did not take a genetic test.
Responses regarding insurance deciding on coverage sounded a consistent theme:
inconsistency in coverage and reimbursement decisions by payers (insurers and health
plans):
Dancingpoodle wrote, “The insurance company said they wouldn't cover the genetic testing
since there was no family history and the cost was so high.”
Jonab wrote, “I have called my insurer to see if I am covered, and they have told me that I
am covered, if it's ‘medically necessary’.”
Rrose wrote, “My insurance company did not cover the cost of the test. The cost to me was
$2500. They told me at the time it was because Athena was not one of their preferred
providers. I was required to pay the entire amount upfront, directly to Athena Labs.”
Should genetic testing have been prescribed earlier?
Users were generally well informed about the various diseases presenting as ataxia and the
limitations surrounding current diagnostic methodology. Most users had ataxia or lived with
someone who did. They understood that over two dozen variants of SCA had been
identified, 12 of which could be genetically tested. They also understood and agreed that
these tests should not be prescribed as a screening test for ataxia because a substantial
clinical threshold needed to be crossed before a genetic test was warranted. When asked if
their neurologist should have prescribed a genetic test earlier, three patients responded that
while they would prefer to have the diagnosis made clear earlier, their neurologist ordered
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genetic testing at the appropriate time. Two patients stated they went through multiple
neurologists to get genetic testing ordered, although both came up negative for a known
SCA variant.
How has genetic testing for SCA affected you?
Having an undiagnosed progressive neurological condition is frightening and disheartening,
yet the users on the forum seemed patient. Diagnosis was an important uncertainty in the
lives of many forum participants. Many had been seeking a diagnosis of their symptoms for
years. Many did not have a diagnosis for their ataxia and other symptoms despite having
undergone extensive diagnostic evaluation, including genetic testing. Despite this, patients
encouraged one another regularly to continue the quest for precise diagnosis. In their view, a
positive or negative result on a diagnostic test helped and also advanced medical practice for
future patients. They fully understood the lack of cure or prevention for any type of SCA
and viewed their participation as essential to changing this.
For participants who received a positive result on a genetic test for SCA, many described
complex emotions. A positive result can give knowledge about the disease and its prognosis,
but there is no cure.
Marjorienye wrote, “First, when I was diagnosed and then more so as my symptoms have
worsened, I've felt more and more helpless to fight what is happening to me. I like to at least
be somewhat knowledgeable about the disease that's wringing the freedom out of my life,
since there's very little I can do to fight it. There's no surgery I can have, no experimental
drugs, and rehabilitative techniques will only slow things down, not cure me. Sometimes it
seems like knowledge is all I can depend on.”
Many of the positive results came from users who had a relative with a specific form of SCA
already diagnosed through genetic testing. The result was particularly difficult if the patient
was asymptomatic (meaning that the test was presymptomatic) or if they had children of
their own.25, 26
Rrose stated, “Having a definite diagnosis is helpful is some ways, as I tend to focus my
research, but troubling in other ways with respect to my children. They know I have the
same thing as their grandmother, but the whole question of when to tell them they can be
tested is very difficult. How do you tell three young men 20, 18 and 16 with no symptoms,
to have testing done that might change the course of their life decisions? I'm not sure I have
the answer to that.”
The benefits of a positive result included certainty of diagnosis, clearer prognosis, and
information relevant to family planning decisions. The variable severity of SCA among
subtypes meant that knowing which type a patient has could have a significant impact on
almost every aspect of their life. For example, a patient with SCA6 can expect slow
deterioration with relatively mild secondary symptoms.6 The SCA6 patient may be able to
continue working a job not requiring much physical exertion. A diagnosis of SCA3,
however, carries a much worse prognosis. A patient can expect to lose mobility in 5–10
years and face rapid progression of secondary symptoms that often leave the patient unable
to work. For a younger or asymptomatic patient, a diagnosis of SCA3 may change long-term
life planning. Dr. Burke reflected that some patients reevaluate their lives based upon the
expected years of functionality. Some patients ask him, “Why should I go to college if I
know that in 20 years I’ll be in a wheelchair?”
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Do you feel you have access to genetic testing taking into consideration financial
constraints?
A majority of the responses from the forum stated that even with genetic tests costing as
much as $7,300, genetic testing was accessible. In some cases patients only required a single
genetic test for a specific SCA variant. These tests, when performed by Athena, cost the
patients from $88 to $440 depending on insurance reimbursement and Patient Protection
Program (PPP) enrollment. Four of five patients who had a single test performed felt the
price was reasonable even if the out-of-pocket expense was the full $480 cost of the test, that
is, without insurance coverage or price reduction through the PPP.
For a patient who did not have a positive diagnosis in their family history, the Complete
Ataxia Panel, with its $7,300 price tag, might be the prescribed diagnostic test. If insurance
covered the test or the patient successfully enrolls in the PPP, the patient responsibility was
$1,500. There were relatively few complaints about the price on the forum. Some comments,
however, implied that $1,500 would inflict hardship on their family, especially considering
the likely negative result.
Dancingpoodle wrote, “I suppose if I felt the test would help cure me if I knew what I had, I
would take out a loan to have it done, but since there are no cures at the moment, I don't see
a reason for putting that financial burden on my family.”
Some paid for a complete ataxia panel without any contribution from insurance or the PPP.
Such patients included some who got testing from sources other than Athena. Another group
of people appeared to be eligible for Athena’s PPP but were unaware of the price reduction
available. They assumed that denial by insurance was the end of the story, and both the
patient and neurologist were unaware of the possibility of negotiating with Athena. In these
cases the price of $7,300 reduced testing, with 5 of 9 patients who were rejected by their
insurer deciding to forego it. This indicates that both patients and Athena could benefit from
greater coverage and reimbursement, and more knowledge about payment assistance and
forgiveness programs.
The perceived risk of genetic discrimination is one unfortunate feature of SCA genetic
testing. The survey was done before the Genetic Information Nondiscrimination Act passed
in May 2008 (and it will not begin to take effect until mid-2009, in any event).
Some who sought testing and might have been eligible for Athena’s PPP abstained from
using their insurance because they did not want their insurance company to know they were
being tested for SCA. These patients voluntarily decided to pay for testing out of pocket and
therefore did not qualify for the PPP and often did not qualify for financial hardship
reductions through Athena Access either. While respondents on the forum surely did not
reflect the general public, but highly selected individuals, it appeared the number foregoing
genetic testing might be a significant number among those who would have found clinical
value in the information available from the test. Of patients surveyed who had genetic
testing and had insurance coverage for the testing, 4 out of 7 patients chose not to notify
their insurer (to avoid genetic discrimination for themselves or others in their family). In
such cases, the $7,300 price did appear to result in some people choosing not to get tested.
Whether or not genetic discrimination actually occurred, as no one reported an actual case of
it, perceptions of the risk clearly did lead to decisions not to seek genetic testing. Several
respondents were hopeful that GINA, the Genetic Information Nondiscrimination Act, could
alleviate health insurance and employment discrimination based on genetic testing if it
became law, as it did in May 2008.
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Following are the experiences of two respondents describing their hesitation about getting
genetic testing. One patient (poolgirl) had the testing covered by insurance, then wished she
had not done so due to the possible repercussions if she had tested positive for a SCA
variant.
Poolgirl wrote, “I had the genetic tests done at a very vulnerable point in my work-up and
thankfully they were negative. Given the implications a positive test could have on my
children, had I been thinking clearly, I would not have done the tests or would have
considered paying for them myself to avoid having them on record. I will not do any tests
that become available in the future unless one of my children specifically requests it be done
to help guide them if/when they are thinking of having children and if so, I would probably
do it off the record. I have no problems with my medical insurance but my personal
interaction with my disability company has made me very cynical about trusting any
insurance carrier to do the right thing.”
Another story shows how one patient did not seek insurance reimbursement for her genetic
test out of fear that her family would be labeled as a result. The loss of insurance for future
generations was a major concern.
We note that in this case, health insurance discrimination from a Medicare carrier is unlikely
because Medicare is an entitlement and does not entail medical underwriting. This response
may reflect an incomplete understanding of Medicare. It is possible, however, that
sunnyKay was worried about how a Medicare reimbursement record might affect insurance
status of a younger member of the family not in Medicare. It is unlikely, however, that a
specific Medicare genetic testing reimbursement decision would affect underwriting,
independent of other information potentially in the medical record and available for any
medical underwriting involving another family member. This perception of high risk of
genetic discrimination is therefore probably not an accurate assessment or real risk, but it
also shows that perception of risk can heavily influence the choice to get a genetic test.
SunnyKay wrote, “My mother requested that Athena not bill Medicare because she wanted
to keep the results private for numerous reasons. That is why a payment plan was arranged
instead. My mother not only did not want the health insurance company/Medicare to know
about possible SCA results, she did not want to apply for a handicapped license plate with a
diagnosis of some form of ataxia either. This is in addition to other things she did to keep
anyone from the government or any other unnecessary place from finding out about my
Dad's medical history, which of course becomes our and her children's family medical
history for life.”
CONCLUSIONS
• Both neurologists and patients stressed that inconsistency in coverage and
reimbursement by payers was as a common problem that has real consequences for
patients and their families by reducing access to genetic tests for SCA.
• All three neurologists interviewed agreed that a prescription for SCA genetic
testing was based primarily on best medical practice, and the clinical value of
information, not price. Despite their belief that Athena’s prices are higher than if
SCA were available in their home institution’s laboratory, they did not describe any
reduction in recommending genetic testing, and it was unclear whether lowering the
price of testing to $100 would increase the number of tests they ordered. They
noted, however, that price did affect their patients, who must decide if the value of
the genetic testing information is worth the cost, and so high price reduces
utilization (and if this information is deemed clinically useful, then also access).
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• The neurologists emphasized the care they must take to ensure they never give a
diagnosis of SCA lightly, either positive or negative. An incorrect diagnosis can
have devastating consequences. From the neurologists’ perspective, one advantage
of sending samples to Athena for testing is that the liability risks associated with
the tests themselves are then borne by Athena. However, this transfer of liability
would apply equally to testing sent to any clinical laboratory facility, and is not
unique to Athena.
• When applicable, Athena’s “Patient Protection Program” can reduce the financial
outlay out-of-pocket, and Athena Access is also available for case-by-case review
of hardship. This feature was cited in the patient forum as valuable and may help
explain the relative dearth of complaints about Athena’s pricing. The actual use of
this program is unknown, but statistics from Athena’s 2001 stock offering suggest
85% of revenues derive hospital and other facility billing, rather than direct patient
or insurance payments. Not all patients know about Athena’s Patient Protection
Program, which can reduce patient out-of-pocket outlays to 20% of test price.
Some who do know about it choose not to avail themselves of it for fear of losing
health insurance. However, Athena’s reported financial data suggest this program is
likely applicable to only a small part of Athena’s revenue stream (10–15%), and
proably a roughly comparable fraction of patients. It is also possible that some
patients may not complain about test costs because most of the unreimbursed cost
of testing is absorbed by the institutions that are billed directly for testing by
Athena.
• From the patient perspective, the main benefit of in-house testing would be any
decrease in cost and direct connection between the clinician ordering the tests and
the laboratory performing them. Unlike some other case studies, we do not have
lists of prices for test providers other than Athena. One published study estimated
the cost of ataxia testing at an institution would increase nearly seven-fold if all
patented tests were referred to Athena rather than being performed by the
institution’s laboratory.24 Another estimate of testing price for the five most
common SCA mutations was $1,500 for a university laboratory compared to
$2,300 for Athena.
• Use of genetic testing is reduced by fear of genetic discrimination by insurers,
health plans and employers, which leads some not to seek third-party
reimbursement for genetic tests. This was a factor for roughly half those who had
insurance coverage, and clearly led to some choices to not get genetic testing
despite valuing the clinical information that would result from the tests.
• We cannot discern in most cases whether this fear of genetic discrimination is
warranted or merely perceived. Given the long search for a diagnosis in most cases,
and thus the accumulation of medical records that would in theory be available to
insurers and employers, it could be that the risk attributed to genetic testing
specifically is lower than perceived—not necessarily because the risk is not there,
but because risks of exclusion from health insurance, disability insurance,
employment, or long-term care insurance are present even without the specific
action of taking a genetic test. Seeking reimbursement does trigger payer scrutiny,
and so the risk of genetic discrimination that some respondents attributed to genetic
testing could still be real. Patients expressed a desire for GINA to become law,
echoing the calls from the Genetic Alliance and other groups. Passage of the Act,
however, will affect employment and health insurance, but not other forms of
insurance for disability, life, and long-term care.
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• Not all patients know about Athena’s Patient Protection Program, which can reduce
patient out-of-pocket outlays to 20% of test price. Some who do know about it
choose not to avail themselves of it for fear of losing health insurance. GINA’s
provisions for health insurance may ameliorate this problem when they begin to
take effect in 2009.
• The laboratory director believed that exclusive licensing of patented tests created
significant barriers to patient access. He believed that academic institutions
exclusively licensing patents to single-source providers were short-sighted and did
not take into account that a university can achieve an equivalent royalty stream
without giving exclusive control of their patents to a single company. He asserted
that academic institutions should not accept an exclusive license bid for
technologies that can readily enter the market. He believed this was especially true
for patents on many diagnostic tests, where the scientific advance may simply be a
new combination of nucleotides used as a primer for a previously unidentified
gene.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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FIGURE 1. CLINICAL SCALES USED TO DETERMINE SCA VARIANTS
Many neurologists have attempted to create neurological tests that can increase SCA
diagnose accuracy before attempting genetic testing. From Mashke M et al. Clinical feature
profile of spinocerebellar ataxia type 1–8 predicts genetically defined subtypes. Movement
Disorders 2005. 20(11):1405–1412, at 1410.
Copyright © 2005, John Wiley & Sons, Inc. Reproduced with permission of John Wiley &
Sons, Inc.
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FIGURE 2. DIAGNOSTIC TREE FOR SPINOCEREBELLAR ATAXIA
The diagnostic tree for SCA relies on many different tools. The most powerful remains
family history, as this can quickly bring a patient to genetic testing. Because most ataxias are
sporadic (not due to known inheritable factors), genetic testing does not occur early in the
tree. From Zumrova A. Problems and possibilities in the differential diagnosis of syndrome
spinocerebellar ataxia. Neuro Endocrinol Lett 2005. 26(2): 98–108.
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FIGURE 3. EXAMPLE OF A CEASE AND DESIST LETTER
Athena Diagnostics has protected their intellectual property rights using letters like the
above.
Powell et al. Page 21
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Powell et al. Page 24
TABLE 2
PATENTS ASSOCIATED WITH ATHENA’S COMPLETE ATAXIA PANEL
The Complete Ataxia Panel test for 11 subtypes of SCA, as well as Friedreich’s Ataxia and Early Onset





SCA-1 5741645, 5834183 Regents of the University of Minnesota,
Minneapolis, MN
SCA-2 6251589 SRL, Inc., Tachikawa, Japan







Regents of the University of Minnesota,
Minneapolis, MN
SCA-8 6524791 Regents of the University of Minnesota,
Minneapolis, MN




6150091 Baylor College of Medicine, Houston, TX,
INSERM, Paris, France
Aprataxin 7119186 Athena Diagnostics, Inc., Worcester, MA
Athena Diagnostics controls 11 patents (in bold) for 6 tests for hereditary ataxia by exclusive licenses. It also holds a non-exclusive license to
US6855497 for SCA-10 testing. Additional patents for SCA-2 (US6623927, US6673535 and US6844431) were found in our search that Athena
does not appear to have licensed.
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TABLE 4
SUMMARY OF GENETESTS.ORG LABORATORY DIRECTORY FOR SCA
TESTING
Patented tests are labeled in grey. Both tests performed by Johns Hopkins are used for research purposes only.
Genetic test Utility Reference value CPT codes













SCA5 Detects sequence variations in three exons in the Spectrin (SPTBN2) gene
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